* Brooklyn Immunotherapeutics Inc BTX.OQ BTX.O is
expected
to report results on March 9 (estimated).
* Refinitiv's mean analyst estimate for Brooklyn
Immunotherapeutics Inc is for a loss of 12 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Brooklyn
Immunotherapeutics Inc is $9, about 78.8% above its last
closing price of $1.91.
This summary was machine generated March 7 at 11:35 GMT. All
figures in US dollars unless otherwise stated